Inflammatory biomarkers and bladder cancer prognosis: a systematic review

Masson-Lecomte A, Rava M, Real FX, Hartmann A, Allory Y, Malats N (2014)

Publication Type: Journal article, Review article

Publication year: 2014

Journal

European Urology Elsevier

Book Volume: 66

Pages Range: 1078-91

Journal Issue: 6

DOI: 10.1016/j.eururo.2014.07.033

Abstract

Host immune response has an impact on tumour development and progression. There is interest in the use of inflammatory biomarkers (InfBMs) in cancer care. Although several studies assessing the potential prognostic value of InfBMs in cancer have been published in the past decades, they have had no impact on the management of patients with urothelial bladder carcinoma (UBC).To review and summarise the scientific literature on the prognostic value of tumour, serum, urine, and germline DNA InfBMs on UBC.A systematic review of the literature was performed searching the Medline and Embase databases for original articles published between January 1975 and November 2013. The main inclusion criterion was the provision of a survival analysis (Kaplan-Meier and/or Cox) according to the Reporting Recommendations for Tumor Marker Prognostic Studies guidelines for the assessment of prognostic markers. We focused on markers assessed at least twice in the literature. Findings are reported following Preferred Reporting Items for Systematic Reviews and Meta-analysis guidelines.Overall, 34 publications, mostly retrospective, fulfilled the main inclusion criterion. Main limitations of these studies were missing relevant information about design or analysis and heterogeneous methodology used. Inflammatory cells, costimulatory molecules in tumour cells, and serum cytokines showed prognostic significance, mainly in univariable analyses. High C-reactive protein values were consistently reported as an independent prognostic factor for mortality in invasive UBC.There is a dearth of studies on InfBMs in UBC compared with other tumour types. Evidence suggests that InfBMs may have an impact on the management of patients with UBC. Currently, methodological drawbacks of the studies limit the translational potential of results.In this review, we analysed studies evaluating the impact of inflammatory response on bladder cancer progression. Despite methodological limitations, some inflammatory biomarkers should be further analysed because they hold promise to improve patient care.

Authors with CRIS profile

Arndt Hartmann Lehrstuhl für Allgemeine Pathologie und Pathologische Anatomie

Involved external institutions

Spanish National Cancer Research Centre / Centro Nacional de Investigaciones Oncológicas (CNIO) ES Spain (ES)

How to cite

APA:

Masson-Lecomte, A., Rava, M., Real, F.X., Hartmann, A., Allory, Y., & Malats, N. (2014). Inflammatory biomarkers and bladder cancer prognosis: a systematic review. European Urology, 66(6), 1078-91. https://doi.org/10.1016/j.eururo.2014.07.033

MLA:

Masson-Lecomte, Alexandra, et al. "Inflammatory biomarkers and bladder cancer prognosis: a systematic review." European Urology 66.6 (2014): 1078-91.

BibTeX: Download